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Hypoxia-inducible factors (HIFs) play a critical role in the
development of liver ﬁbrosis. We summarize the important
functions of HIFs in liver ﬁbrosis and focus on the cell-
speciﬁc role of these transcription factors in disease
development.
Liver ﬁbrosis remains a signiﬁcant clinical problem in the
United States and throughout the world. Although impor-
tant advances in the understanding of this disease have
been made, no effective pharmacologic agents have been
developed that directly prevent or reverse the ﬁbrotic
process. Many of the successes in liver ﬁbrosis treatment
have been targeted toward treating the cause of ﬁbrosis,
such as the development of new antivirals that eradicate
hepatitis virus. For many patients, however, this is not
feasible, so a liver transplant remains the only viable op-
tion. Thus, there is a critical need to identify new thera-
peutic targets that will slow or reverse the progression of
ﬁbrosis in such patients. Research over the last 16 years
has identiﬁed hypoxia-inducible factors (HIFs) as key
transcription factors that drive many aspects of liver
ﬁbrosis, making them potential targets of therapy. In this
review, we discuss the latest work on HIFs and liver
ﬁbrosis, including the cell-speciﬁc functions of these
transcription factors in the development of liver ﬁbrosis.
(Cell Mol Gastroenterol Hepatol 2015;1:589–597; http://
dx.doi.org/10.1016/j.jcmgh.2015.09.005)
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All these agents produce hepatocellular injury to some
extent, which initiates a reparative process. Part of this
process involves differentiation of hepatic stellate cells
(HSCs) into myoﬁbroblasts, a process called “activation.”1,2
In instances of biliary injury, in addition to HSCs, portal ﬁ-
broblasts become activated.3,4 Once this occurs, these cells
begin to proliferate, migrate, and synthesize collagen, which
provides the initial matrix for repair. After an acute hepatic
insult, the excess collagen is removed, and the myoﬁbro-
blasts revert back to a quiescent phenotype. If liver injury
persists, however, collagen continues to become deposited,resulting in ﬁbrosis and ultimately cirrhosis that may lead to
liver failure or cancer. Many of the mediators that regulate
HSC activation have been identiﬁed (for a comprehensive
review, see Friedman2), but the mechanisms that regulate
production of these mediators during acute and chronic
injury are not fully understood. Recent studies, however,
have demonstrated that a group of transcription factors
called hypoxia-inducible factors (HIFs) may be critical for
this process.5
To adapt to varying levels of oxygen in the environment,
organisms have developed oxygen-sensing systems that
trigger adaptive transcriptional responses to maintain ho-
meostatic conditions. These systems use HIF transcription
factors, which are heterodimeric transcription factor com-
plexes composed of a and b subunits.6,7 During hypoxia, HIF
transcriptional activity leads to enhanced expression of
various genes involved in cellular functions aimed at
maintaining homeostasis, such as metabolism, proliferation,
and migration. There are three known HIF transcription fac-
tors: HIF-1a, HIF-2a, and HIF-3a.8–10 Of these three, HIF-1a
and HIF-2a are the best characterized. These a subunits
heterodimerize with HIF-1b, also called the aryl hydrocar-
bon nuclear transporter, before they are able to regulate
gene expression.6,7 HIF-1b is constitutively expressed and
present in excess, whereas the a subunit is regulated in an
oxygen-dependent manner.
Under normoxic conditions, the HIF a subunit is imme-
diately targeted for degradation by the 26S proteasome.11 In
hypoxic conditions, however, the mechanisms that target
the HIF a subunit for degradation are inhibited, allowing the
HIF a unit to become stabilized and translocate to the nu-
cleus. Once it enters the nucleus, it dimerizes with HIF-1b,
forming a HIF complex that binds to speciﬁc hypoxia-
responsive elements in target genes.7,8
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1a Activation in the Liver During Injury
Several studies, including our own, have demonstrated
that regions of hypoxia develop in the liver after acute liver
injury. Early studies showed that hypoxia develops in the
liver after alcohol treatment.12,13 Later studies showed that
damage to the liver with compounds such as monocrotaline
or acetaminophen also produce regions of hypoxia.14,15 The
mechanism by which this occurs is not known, but it most
likely results from disruption of the hepatic architecture,
which impedes blood ﬂow through damaged regions; acti-
vation of the coagulation system, which leads to ﬁbrin clot
formation in the vasculature; and possibly production of
vasoactive mediators that modulate hepatic blood ﬂow to
regions of injury.16 To identify regions of hypoxia, many of
these studies have used a chemical called pimonidazole,
marketed as hypoxyprobe.17 In addition to this method,
activation of HIF-1a has been used as a surrogate marker of
hypoxia. HIF-1a has been detected in the livers of mice
treated with ethanol, acetaminophen, or carbon tetrachlo-
ride (CCl4).
13,18–20
In addition to hypoxia, however, HIF-1a can be activated
in cells by other mediators, including cytokines, growth
factors, and oxidative stress. Accordingly, caution should be
used before equating HIF-1a activation with hypoxia. In fact,
HIF-1a is activated in the liver after acetaminophen and
CCl4 treatment before the development of hypoxia, sug-
gesting an important role for other mechanisms of HIF-1a
regulation in the liver after exposure to these toxicants.18,20
Similar to acute injury, studies have shown that hypoxia
is present in the liver during chronic injury. Rosmorduc
et al21,22 originally showed hypoxia in the liver after chronic
treatment of rats with diethynitrosamine or after bile duct
ligation (BDL), both of which produce severe ﬁbrosis. We
later conﬁrmed these ﬁndings and demonstrated that HIF-
1a is activated in several cell types in the liver after BDL.5 In
particular, HIF-1a was activated in macrophages and he-
patocytes within and at the periphery of regions of necrosis,
both areas where hypoxia was present. In addition to animal
models, we detected HIF-1a protein in hepatocytes and
scar-associated macrophages near regions of bridging
ﬁbrosis in livers from patients with primary biliary cirrhosis
or primary sclerosing cholangitis.23 We also detected
HIF-1a in a-smooth muscle actin (a-SMA) expressing myo-
ﬁbroblasts within regions of bridging ﬁbrosis.23 Because
HIF-1a regulates a number of genes that have been impli-
cated in ﬁbrosis development, including, platelet-derived
growth factor (PDGF),24 ﬁbroblast growth factor-2
(FGF-2),25 vascular endothelial growth factor (VEGF),26
plasminogen activator inhibitor-1 (PAI-1),27 and many
others, our laboratory and others have conducted studies to
evaluate the role of HIF-1a in the development of ﬁbrosis.Role of Hypoxia-Inducible Factor-1a in
the Development of Liver Fibrosis
HIF-1a knockout mice die during embryonic develop-
ment.28 Accordingly, to test the hypothesis that HIF-1acontributes to the development of liver ﬁbrosis, our labo-
ratory used Cre-lox technology to knockout HIF-1a in adult
mice. In this study, HIF-1a ﬂoxed mice were crossed with
mice that express Cre recombinase under control of the Mx
interferon-inducible promoter.5 In these mice, treatment
with polyinosinic-polycytidylic acid ubiquitously increases
Cre recombinase in most cell types.29 These mice and con-
trol mice that did not receive polyinosinic-polycytidylic acid
were subjected to BDL. In HIF-1a-deﬁcient mice, liver
ﬁbrosis was substantially reduced, which demonstrated for
the ﬁrst time a key role for HIF-1a in the development of
liver ﬁbrosis in vivo.5 Deletion of HIF-1a prevented up-
regulation of several key proﬁbrotic mediators including
PDGF-A, PDGF-B, PAI-1, and FGF-2.5 All these proteins have
been implicated in the development of liver ﬁbrosis, sug-
gesting that HIF-1a may promote ﬁbrosis by regulating
expression of these genes.30–33 In fact, studies have shown
that these genes are directly regulated by HIF-1a in some
cell types.24,25,27 Although this study indicated a key role for
HIF-1a in the development of liver ﬁbrosis, the cell-speciﬁc
role of HIF-1a in the development of this disease remained
unknown.
Proﬁbrotic Function of Hypoxia-
Inducible Factors in Hepatocytes
As discussed earlier, HIF-1a is activated in hepatocytes
in mice subjected to BDL and in patients with primary
biliary cirrhosis and primary sclerosing cholangitis.5,23 Early
studies by Kietzmann et al27 demonstrated that HIF-1a is
activated in hypoxic hepatocytes and that HIF-1a directly
regulates PAI-1 in these cells. Our laboratory conﬁrmed
these ﬁndings and also showed that HIF-2a was activated in
hypoxic hepatocytes and was needed for full induction of
PAI-1 in these cells.34 In addition to PAI-1, our studies
demonstrated that hypoxia up-regulates VEGF,
adrenomedullin-1 (ADM-1), and ADM-2 in a HIF-1a and
HIF-2a-dependent manner.34 Interestingly, although HIF-1a
regulates PDGF-A and PDGF-B in some cell types, these were
not increased in hypoxic hepatocytes.
Our studies also showed for the ﬁrst time an interaction
between the HIF and transforming growth factor b (TGF-b)
signaling pathways. In this study, our laboratory demon-
strated that hypoxic hepatocytes activate latent TGF-b1 in a
HIF-dependent manner.35 Although the mechanism by
which this occurs is not fully understood, we have evidence
that hypoxia increases expression of several matrix metal-
loproteinases and thrombospondin-1 in hepatocytes (Cop-
ple, unpublished observations), all of which can activate
latent TGF-b1.36–38
Collectively, these in vitro studies demonstrated that
HIF-1a and HIF-2a are activated in hypoxic hepatocytes and
regulate expression of PAI-1 and VEGF as well as regulate
activation of latent TGF-b1, which could promote the
development of liver ﬁbrosis (Figure 1). Since these studies,
other laboratories have investigated the role of hepatocyte
HIFs in the development of liver ﬁbrosis in vivo.
In a study by Scott et al,39 HIF-1b (aryl hydrocarbon
nuclear transporter) ﬂoxed mice were crossed with mice
Figure 1. Potential proﬁbrotic functions of hypoxia-inducible factors (HIFs) in hepatocytes and macrophages. Various
hepatotoxicants produce hypoxia or stimulate release of mediators that activate HIFs in hepatocytes and M1-like inﬂammatory
macrophages. In hepatocytes, HIF-1a and HIF-2a regulate vascular endothelial growth factor (VEGF). In addition, HIFs in
hepatocytes regulate matrix metalloproteinases and thrombospondin 1 (TSP-1), which convert latent transforming growth
factor b1 (TGF-b1) to active TGF-b1. In macrophages, HIF-1a regulates production of VEGF, platelet-derived growth factor B
(PDGF-B), and ﬁbroblast growth factor 2 (FGF-2), which promote ﬁbrosis by affecting hepatic stellate cell activation, prolif-
eration, and collagen production.
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min promoter to generate hepatocyte-speciﬁc HIF-1b
knockout mice. As discussed earlier, HIF-1b hetero-
dimerizes with the basic helix-loop-helix-PER-ARNT-SIM
(bHLH/PAS) transcription factor family, which includes
HIFs, and is thus required for both HIF-1a and HIF-2a
transcriptional activity.6,9 Mice with and without deletion
of HIF-1b in hepatocytes were treated with the hep-
atotoxicant thioacetamide to induce liver ﬁbrosis.
Although the pattern of ﬁbrosis was similar in both, there
was a decrease in macrophage inﬁltration as well as a
decrease in the mRNA expression of proﬁbrotic genes,
including TGF-b1 and TGF-b2, collagen type 1 and 5, and
tissue inhibitor of metalloproteinases 1 and 5 (Timp1
and 5) in hepatocyte-speciﬁc HIF-1b knockout mice.39
These results provided support for the importance of
HIFs in regulating proﬁbrotic gene expression in hepato-
cytes in vivo after liver injury.
Further studies conducted by Roychowdhury et al40 also
suggested an important role for hepatocyte HIF-1a in the
development of ﬁbrosis. In their study, hepatocyte-speciﬁc
HIF-1a–deﬁcient mice were fed ethanol concomitantly
with CCl4 treatment, resulting in the ampliﬁcation of CCl4-
induced hepatic ﬁbrosis. Hepatocyte-speciﬁc HIF-1a–
deﬁciency prevented the ethanol-induced increase in
CCl4-induced ﬁbrosis compared with control mice, as
measured by mRNA and protein levels of both type I collagen
and a-SMA, indicating an important role for hepatocyte HIF-
1a in the development of liver ﬁbrosis in this model.40
However, when mice were treated with CCl4 alone without
ethanol, HIF-1a deﬁciency in hepatocytes did not reduce liver
ﬁbrosis, which may indicate that hypoxia resulting from
ethanol metabolism may enhance HIF-1a activation inhepatocytes after CCl4 treatment, allowing HIF-1a to play a
greater role in the development of liver ﬁbrosis.40
Studies by Qu et al41 found that HIF-2a in hepatocytes
may also be important for progression of ﬁbrosis. In these
studies, hepatocyte-speciﬁc Vhl knockout mice were pro-
duced, which results in constitutively activate HIF-1a and
HIF-2a in hepatocytes.42 Gene expression proﬁles were then
assessed in the livers of control mice and hepatocyte-
speciﬁc Vhl knockout mice.41 Numerous genes critical to
the development of liver ﬁbrosis were found to be up-
regulated. These included genes important for collagen
formation, such as procollagen-lysine 2,oxoglutarate
5-dioxygenase 2 (PLOD2) and transglutaminase 2 (TGM2)
as well as a-SMA.41 Furthermore, Vhl-disrupted mice fed an
ethanol diet produced an increase in ﬁbrosis. This increase
was completely prevented in hepatocyte-speciﬁc Vhl-Hif-2a
double knockout mice, but not in hepatocyte-speciﬁc Vhl-
Hif-1a double knockout mice.41 Together, these data indi-
cated that HIF-2a activation in hepatocytes is important for
the development of liver ﬁbrosis in this model.41
One caveat of this study, however, was that although
deletion of HIF-2a did prevent an increase in ﬁbrosis, it also
resulted in reduced liver injury overall. Because liver injury is
the driving factor leading to ﬁbrosis, it is possible that HIF-2a
did not play a direct role in the progression of ﬁbrosis, but
rather played a role in producing liver injury. Further studies
are needed to more deﬁnitively elucidate the role of HIF-2a
in hepatocytes in the development of ﬁbrosis.Kupffer Cells
Kupffer cells are resident macrophages of the liver.
Although these cells perform key beneﬁcial functions, they
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disorders, including ischemia-reperfusion injury, toxin-
induced liver injury, fatty liver disease, and liver
ﬁbrosis.43,44 Rivera et al43 were the ﬁrst to show a key role
for macrophages in the development of liver ﬁbrosis in rats
after chronic CCl4 treatment. Subsequent studies have
conﬁrmed these results, reafﬁrming an essential role for
these cells in the development of liver ﬁbrosis.45 Work from
Karlmark et al46 indicated that the macrophage population
that promoted ﬁbrosis was recruited from bone marrow in a
manner dependent on C-C chemokine receptor type 2 (Ccr2)
and type 6 (Ccr6). Immunophenotyping of these cells indi-
cated that they were CD11bþF4/80þGr1þ monocyte-
derived macrophages.
Although these studies have clearly indicated that mac-
rophages are important for the development of ﬁbrosis, the
mechanism by which they contribute to this process was not
known. Early studies by Friedman and Arthur31 showed
that conditioned medium from cultured Kupffer cells stim-
ulated HSC proliferation in culture in a PDGF-dependent
manner. In addition, studies provided evidence that intra-
hepatic CD11bþF4/80þGr1þ macrophages could stimulate
HSCs to produce collagen in a TGF-b-dependent manner.46
Consistent with these studies, immunohistochemical
studies and in situ hybridization techniques have shown
that macrophages express TGF-b and PDGFs in the liver
during the genesis of ﬁbrosis.47,48 Collectively, these studies
demonstrated that macrophages are important for the
development of ﬁbrosis and that they may contribute to
ﬁbrosis by producing growth factors that stimulate HSC
proliferation and collagen production. However, the mech-
anism by which chronic liver injury stimulated these cells to
produce proﬁbrotic mediators remained unknown.
As discussed earlier, our studies demonstrated that HIF-1a
was activated in scar-associated macrophages in both
mice and humans with liver ﬁbrosis.5,23 In subsequent
studies, we showed that exposure of Kupffer cells to hypoxia
in vitro activated HIF-1a but not HIF-2a, suggesting that
HIF-1a signaling may predominate in Kupffer cells from
nondiseased livers.49 This, however, could potentially
change in diseased livers. In the presence of certain cyto-
kines, macrophages polarize to different phenotypes,
including classically activated (M1) and alternatively acti-
vated (M2) macrophages. Takeda et al50 showed that HIF-1a
is up-regulated and HIF-2a is down-regulated in classically
activated macrophages, whereas HIF-2a is up-regulated and
HIF-1a down-regulated in alternatively activated macro-
phages. It is possible that Kupffer cells in nondiseased livers
are skewed toward a classically activated phenotype, which
may explain the lack of HIF-2a activation in these cells. In
diseased livers, however, we have observed hepatic mac-
rophages with activated HIF-1a or HIF-2a, indicating that
both transcription factors can be activated in hepatic mac-
rophages in vivo after injury (Copple, Mochizuki, and Roth,
unpublished observation).
Because HIF-1a and HIF-2a regulate overlapping and
distinct sets of genes, it would be interesting to evaluate the
pattern of gene expression in hypoxic Kupffer cells either
skewed toward a classic phenotype with activated HIF-1a oran alternative phenotype with activated HIF-2a. It is
possible that these two macrophage populations may play
very different roles in liver disease in part due to differential
expression of HIF-1a and HIF-2a.
Studies have shown that hypoxic Kupffer cells produce
proﬁbrotic mediators in vitro. Our laboratory showed that
in vitro exposure of Kupffer cells to hypoxia increased
expression of several genes involved in angiogenesis,
including VEGF and angiopoietin-1, in a HIF-dependent
manner.49 In addition, PDGF-B was also up-regulated in
hypoxic Kupffer cells in a HIF-dependent manner.49 In mice
subjected to BDL, knocking out HIF-1b selectively in mac-
rophages using Cre/lox did not affect liver injury, markers
of cholestasis, or hepatic inﬂammation, including up-
regulation of cytokines and hepatic neutrophil and macro-
phage accumulation.23 Deletion of HIF-1b did, however,
reduce liver ﬁbrosis as measured by type I collagen and
a-SMA mRNA and protein levels.23 In addition, knocking out
HIF-1b in macrophages prevented an increase in PDGF-B
mRNA and protein.23 It also prevented up-regulation of
FGF-2, another proﬁbrotic growth factor, but did not affect
levels of active TGF-b protein.23 Similar results were
observed in mice in which HIF-1a was knocked out in
macrophages, suggesting that HIF-1a in macrophages is
proﬁbrotic (Figure 1).23 This is consistent with reports
suggesting that classically activated, inﬂammatory macro-
phages primarily promote ﬁbrosis.46 As mentioned earlier,
HIF-1a is up-regulated in classically activated macrophages.
It would be interesting, however, to investigate the role of
HIF-2a in macrophages and determine whether it may play
an opposing role and promotes ﬁbrosis reversal.Hepatic Stellate Cells
Despite being originally described in the 19th century, it
was not until 1985 that Friedman et al1 discovered that
HSCs are the main collagen-producing cell type in the liver.
Recent studies using sophisticated cell-tracing techniques
have further conﬁrmed the importance of these cells in
collagen deposition during ﬁbrosis.51 During quiescence,
these cells store and release retinoids. After liver injury,
these cells become activated and differentiate into a-SMA–
expressing myoﬁbroblasts that produce collagen, prolifer-
ate, and migrate throughout the liver.2 Because liver injury
produces regions of hypoxia, Corpechot et al22 tested the
hypothesis that hypoxia stimulates HSCs to produce
collagen. In this study, exposure of rat HSCs to hypoxia
in vitro up-regulated type I collagen, indicating that hypoxia
is a stimulus for collagen production by these cell types. In
addition, we recently conﬁrmed these ﬁndings in culture-
activated, primary human HSCs (Copple, unpublished
ﬁndings).
Although this process is not fully understood, it most
likely evolved to provide an initial structural matrix to
facilitate repair processes, such as angiogenesis. During
chronic injury, however, persistent hypoxia provides a
continuous stimulus for collagen production by HSCs,
leading to ﬁbrosis. A later study by Shi et al52 conﬁrmed that
hypoxia up-regulates collagen in a human HSC line, LX-2
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suggesting that hypoxia stimulates autocrine production of
TGF-b, which could stimulate collagen production.52 This
same group also observed an increase in matrix metal-
loproteinase 2, which could process TGF-b to its active
form.52 Whether these processes require HIFs and occur
in vivo during ﬁbrosis development, however, remain to be
determined.
Because of the results described here, our laboratory
next determined whether HIFs are activated in hypoxic
HSCs. In these studies, exposure of culture-activated, pri-
mary mouse HSCs to hypoxia activated both HIF-1a and
HIF-2a.53 Hypoxia also increased the expression of several
genes that could contribute to ﬁbrosis development. For
instance, hypoxia increased expression of two genes
involved in collagen metabolism, prolyl-4-hypdroxylase a1
and prolyl-4-hydroxylase a2, which are key enzymes that
contribute to the formation of stable collagen triple heli-
ces.53 As expected, hypoxia also increased expression of
several genes involved in angiogenesis, including VEGF,
angiopoietin-like-4, placental growth factor, and
macrophage-migration inhibitory factor.53
It has been proposed that angiogenesis is a critical factor
in the development of liver ﬁbrosis,21 although this remains
a rather controversial area. For instance VEGF has been
shown to stimulate HSCs to produce collagen, to proliferate,
and to migrate in vitro.54 Furthermore, neutralization of
VEGF was shown to reduce ﬁbrosis in CCl4-treated mice.
55
More recent studies, however, have shown that VEGF is
critical for reversal of ﬁbrosis.56,57 The antiﬁbrotic effects of
VEGF are most likely due to effects of VEGF on sinusoidal
endothelial cells rather than HSCs. Accordingly, the impor-
tance of VEGF and angiogenesis to liver ﬁbrosis is compli-
cated and remains an evolving ﬁeld.
In addition to proangiogenic mediators, hypoxia
increased the expression of receptors involved in HSC
migration and activation. For instance, hypoxia increased
the expression of the chemokine receptors Ccr1 and
Ccr5.53 In the presence of chemokines, activation of these
receptors stimulates HSC migration. In support of a role for
these receptors in the development of ﬁbrosis, it was
shown that Ccr1 and Ccr5 knockout mice have reduced
liver ﬁbrosis.58 Two other receptors of interest were
increased by hypoxia in HSCs. These were interleukin-13
receptor a1 and adrenergic receptor a2b, which are acti-
vated by interleukin-13 and catecholamines, respec-
tively.53 In vitro, activation of these receptors on HSCs
stimulates collagen production, and in vivo both these
pathways have been shown to play an important role in
liver ﬁbrosis development.59–61
Although up-regulation of some of the genes described
here required HIF-1a, up-regulation of some did not require
HIF-1a, suggesting an important role for HIF-2a or poten-
tially other hypoxia-regulated transcription factors in
regulation of these genes.53 Of particular interest, up-
regulation of many of these genes by hypoxia only
occurred in culture-activated HSCs and did not occur in
quiescent HSCs, suggesting that HSC activation increases the
sensitivity of HSCs to HIF-mediated gene expressionchanges.53 The mechanism by which this occurs is not
known, but it may result from changes in histone modiﬁ-
cations or DNA methylation changes that modify access of
HIFs to the promoters of certain HIF-regulated genes in
activated HSCs.
In addition to the genes already described, hypoxia also
increased expression of genes that have the potential to
globally affect HSC function in a profound manner. Two of
these were the Jumonji domain-containing proteins Jmjd6
and Jmjd1a.53 Jmjd6 regulates mRNA spicing, and Jmjd1a is
a histone demethylase.62,63 Up-regulation of Jmjd1a by HIFs
could increase expression of a number of genes by modi-
fying histone methylation, whereas up-regulation of Jmjd6
could promote the formation of alternatively spliced mRNAs
that code for proteins with modiﬁed functions that promote
ﬁbrosis.
In addition to Jumoni proteins, hypoxia increased
expression of regulator of G-protein signaling 2 (Rgs2) and
Rgs4.53 These proteins act as GTPase-activating proteins for
G protein a subunits, thereby decreasing signaling by Gia,
Goa, and Gqa subtypes.64 Up-regulation of Rgs proteins
could substantially affect signaling by G protein-coupled
receptors in HSCs. The importance of this in regulating
HSC function during the development of ﬁbrosis remains to
be determined. The various processes regulated by HIFs in
HSCs that may contribute to ﬁbrosis are summarized in
Figure 2.
Although numerous genes were increased in hypoxic
HSCs, surprisingly few were decreased by hypoxia. Two
genes of particular interest that were decreased by hypoxia
were hepatocyte growth factor (HGF) and a1-integrin.53
HGF is important for liver regeneration, and studies have
shown that HSCs are a source of HGF during regener-
ation.65–67 In addition to our study, Corpechot et al68
demonstrated in 2002 that hypoxia decreases HGF in
hypoxic HSCs. In this study, they proposed that decreased
HGF expression in hypoxic HSCs may contribute to liver
regeneration failure in cirrhotic livers.68 Alpha-1-integrin
is a receptor for collagen, and studies have shown that
collagen production by ﬁbroblasts from a1-integrin
knockout mice is enhanced, suggesting a role for this re-
ceptor in feedback inhibition of collagen production.69 The
importance of the decrease in a1-integrin in hypoxic HSCs,
however, remains to be determined. Furthermore, whether
HIF-1a contributes to the reduction in HGF and a1-integrin
is not known.
In consideration of the impact of hypoxia and HIF acti-
vation on the function of HSCs in vitro, studies were con-
ducted to evaluate the role of HIF-1a in HSCs in vivo on the
development of liver ﬁbrosis. In these studies, HIF-1a ﬂoxed
mice were crossed with mice that express Cre recombinase
under the glial ﬁbrillary acidic protein promoter, which, in
the liver, is only expressed by HSCs.20 This resulted in
deletion of HIF-1a in HSCs but no other liver cell types.
Treatment of control mice in this study with a single hep-
atotoxic dose of CCl4 increased the expression of types I, III,
and IV collagens by 48 hours after treatment.20 Deletion of
HIF-1a in HSCs completely prevented up-regulation of all
three collagens in the liver at this time point.20 Surprisingly,
Figure 2. Genes regulated by hypoxia-inducible factor 1a (HIF-1a) in hepatic stellate cells that may promote ﬁbrosis.
(See the text for full details.)
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collagen mRNA and protein were much greater in the livers
of mice in which HIF-1a was knocked out in HSCs.20 In
addition, there were greater levels of a-SMA mRNA and
protein, indicating enhanced HSC activation.20
These results were quite contrary to in vitro studies and
suggested a potential role for HIF-1a in limiting HSC acti-
vation and collagen production in vivo after liver injury.
Further analysis, however, demonstrated that there was a
failure of macrophages to become activated in the livers of
these mice, which prevented removal of necrotic hepato-
cytes from the liver.20 We proposed that the persistence of
necrotic cells most likely maintained HSC activation and
enhanced production of collagen in mice deﬁcient in HIF-1a
in HSCs.
Interestingly, this phenotype is also observed in plas-
minogen and urokinase plasminogen activator knockout
mice, where there is a failure to clear necrotic hepatocytes,
leading to enhanced collagen production.70–72 Accordingly,
while HIF-1a appeared to be important for collagen up-
regulation early after injury, it also stimulated HSCs to
produce a HIF-1a–dependent factor(s) that activatedmacrophages, which is essential for phagocytic removal of
necrotic hepatocytes. The mechanism by which this occurs
is not known; however, considering the similar phenotype
in mice deﬁcient in plasmin, it is possible that HIF-1a acti-
vation in HSCs modulates plasmin formation after injury.
Summary and Perspectives for
Targeting Hypoxia-Inducible Factors
as a Therapy for Liver Fibrosis
Research over the past 16 years has provided important
information on the role of HIFs in the development of liver
ﬁbrosis. This work has provided evidence that HIF-1a reg-
ulates a number of important proﬁbrotic mediators in he-
patocytes, HSCs, and Kupffer cells. It remains to be
determined whether HIF-1a activation in other cell types
contributes to this disease. For instance, VEGF, a key HIF-
target gene, is increased in cholangiocytes after BDL.73
Whether this requires HIF-1a is not known. HIF-1a also
regulates the function of various immune cell types,
including T cells, natural killer T cells, and B cells, which
may be important for ﬁbrosis.74–77 Furthermore, very little
November 2015 HIF in Liver Fibrosis 595is known about the role of HIF-2a in liver ﬁbrosis and in
which cells HIF-2a is activated. Finally, there is a clear link
between HIF-1a and HIF-2a activation and the development
of cancer. Because cirrhosis can often progress to hepato-
cellular carcinoma, it would be interesting to determine
whether HIFs are an important driving force for the pro-
gression of cirrhosis to cancer. Studies have shown that
constitutive activation of HIF-1a and HIF-2a in hepatocytes
produces hemangiomas in the liver, lending support for a
role of HIFs in cancer development in the liver.78 Over the
next several years, research should begin to ﬁll these
knowledge gaps.
Also, it is unclear whether pharmacologic inhibition of
HIFs would be an effective therapy for liver ﬁbrosis. Only
one study has addressed this topic thus far. In a rat model of
transarterial chemoembolization in which rats are treated
with CCl4 and subjected to hepatic artery ligation, a putative
HIF-1a inhibitor called LW6 prevented progression of liver
ﬁbrosis when started 2 weeks after the initiation of liver
disease.79 Although these results are exciting, additional
studies with other models of liver ﬁbrosis and other well-
characterized HIF inhibitors need to be conducted before
HIFs are validated targets for liver ﬁbrosis therapy.
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